Hydroquinidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Hydroquinidine is a medication indicated in the maintenance of a normal sinus rhythm, as well as the treatment and prevention of abnormal rhythm.

Generic Name
Hydroquinidine
DrugBank Accession Number
DB15300
Background

Hydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 326.44
Monoisotopic: 326.199428085
Chemical Formula
C20H26N2O2
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAtrial fibrillation or flutter•••••••••••••••••••••••
Prophylaxis ofParoxysmal supraventricular tachycardia•••••••••••••••••••••••
Maintenance ofSinus rhythm•••••••••••••••••••••••
Maintenance ofSinus rhythm•••••••••••••••••••••••
Treatment ofSupraventricular arrhythmias•••••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololAcebutolol may increase the arrhythmogenic activities of Hydroquinidine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Hydroquinidine.
AdenosineAdenosine may increase the arrhythmogenic activities of Hydroquinidine.
AjmalineAjmaline may increase the arrhythmogenic activities of Hydroquinidine.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Hydroquinidine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
C01BA13 — Hydroquinidine
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8P68XPY4HG
CAS number
1435-55-8
InChI Key
LJOQGZACKSYWCH-LHHVKLHASA-N
InChI
InChI=1S/C20H26N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3/t13-,14-,19+,20-/m0/s1
IUPAC Name
(S)-[(1S,2R,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
SMILES
[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2CC)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12

References

General References
  1. AIFA Product Information: IDROCHINIDINA LIRCA (hydroquinidine hydrochloride) oral tablet [Link]
ChemSpider
82624
RxNav
27220
ChEMBL
CHEMBL531472
ZINC
ZINC000003977899
Wikipedia
Dihydroquinidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentBrugada Syndrome (BrS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Cream
TabletOral150 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.312 mg/mLALOGPS
logP3.36ALOGPS
logP2.82Chemaxon
logS-3ALOGPS
pKa (Strongest Acidic)13.89Chemaxon
pKa (Strongest Basic)9.18Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area45.59 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity94.65 m3·mol-1Chemaxon
Polarizability36.67 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0009000000-5fd9192ebf49428a6342
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004l-0498000000-0c955987e5cc615a03d5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0009000000-154760bc96c0695902cf
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a70-0938000000-7dc41a151824cf123542
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0230-0921000000-da0b4f0d362a8e5e64c2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0abc-0910000000-a00a1d8b25080afa5400
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-189.9813924
predicted
DarkChem Lite v0.1.0
[M-H]-190.5648924
predicted
DarkChem Lite v0.1.0
[M+H]+190.2063924
predicted
DarkChem Lite v0.1.0
[M+H]+191.1180924
predicted
DarkChem Lite v0.1.0
[M+Na]+190.4913924
predicted
DarkChem Lite v0.1.0
[M+Na]+190.6917924
predicted
DarkChem Lite v0.1.0

Drug created at May 20, 2019 15:09 / Updated at September 25, 2021 23:52